Roche\'s Tecentriq combo shows promise in firstline triplenegative breast cancer

Roche's Tecentriq combo shows promise in first-line triple-negative breast cancer

05:22 EDT 1 Apr 2019 | Pharmafile

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of advanced triple-negative breast cancer (TNBC).

The findings showed that the combination of ipatasertib, Tecentriq (atezolizumab) and chemotherapy (paclitaxel or nab-paclitaxel (Abraxane [paclitaxel albumin-bound particles for injectable suspension]) delivered an objective response rate (ORR) of 73% in the study’s 26 participants, regardless of tumour biomarker status.

Roche\'s Tecentriq combo shows promise in firstline triplenegative breast cancer

Roche's Tecentriq combo shows promise in first-line triple-negative breast cancer

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of advanced triple-negative breast cancer (TNBC).

More From BioPortfolio on "Roche's Tecentriq combo shows promise in first-line triple-negative breast cancer"